Year of investment: 2011
ACS Biomarker targets discovery and validation of novel miRNA and protein-based cardiovascular biomarkers, improving diagnoses and management of cardiac diseases. ACS Biomarker licensed out exclusive rights to BG Medicine on its biomarker Galectin-3 as a prognostic indicator of congestive heart failure.
Year of investment: 2011
Q Chip, based in Cardiff (Wales, UK) commercializes innovative sustained-release drug formulations of injectable therapeutics. The sustained- release can be tailored and administration of the therapeutics is improved. The company was acquired by Midatech Pharma plc in late 2014.
Year of investment: 2010
CellMade develops and commercializes cell biology products and services: human-origin primary cells, co-culture models, customized cell isolation and characterization. CellMade also invests in its own R&D program using its CellInsight platform for identification of targets and biomarkers related to inflammatory pathologies. The company has facilities in Marseille (France) and at the Chemelot Campus.
Year of investment: 2008
Chemtrix BV supplies complete and customized microreactor systems for R&D and commercial manufacturing. Chemtrix’ microreactors enhance process efficiency, energy efficiency and safety of chemical synthesis in the fine chemical and pharmaceutical industries.
Year of investment: 2005
Basic Pharma is an advanced, independent pharmaceutical company primarily engaged in developing, licensing, manufacturing and commercialisation of pharmaceutical and biopharmaceutical products. Basic Pharma delivers a full service package to the Pharmaceutical, Biotech and Medical Device industry.
Year of investment: 2004
In 2009 the company was part of a transaction involving an MBI and which provided a partial exit for shareholders.
The assets were transferred to Fortimedix Holding BV.